The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use

Journal of Dual Diagnosis

Volumn 8, Issue 1, 2012, Pages 50-61

  Koola, Maju Mathew ^a   Wehring, Heidi J ^a   Kelly, Deanna L ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

drug abuse; long acting antipsychotics; nonadherence; relapse; substance use

Indexed keywords

FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE; ZUCLOPENTHIXOL;

COMORBIDITY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; HOSPITALIZATION; HUMAN; META ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84857215033     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1080/15504263.2012.647345     Document Type: Review

References (125)

1. Adams, C. E., Fenton, M. K., Quraishi, S., and, David, A. S. 2001. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. The British Journal of Psychiatry, 179: 290-299. (Pubitemid 32996037)
2. Adrian, M., and, Barry, S. J. 2003. Physical and mental health problems associated with the use of alcohol and drugs. Substance Use & Misuse, 38 (11-13): 1575-1614.
3. Ananth, J., Vandewater, S., Kamal, M., Brodsky, A., Gamal, R., and, Miller, M. 1989. Mixed diagnosis of substance abuse in psychiatric patients. Hospital and Community Psychiatry, 40: 297-299. (Pubitemid 19077138)
4. Arango, C., Bombn, I., González-Salvador, T., Garca-Cabeza, I., and, Bobes, J. 2006. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. European Psychiatry, 21 (1): 34-40. (Pubitemid 43245596)
5. Becker, M. A., Young, M. S., Ochshorn, E., and, Diamond, R. J. 2007. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Administration & Policy in Mental Health, 34 (3): 307-314. (Pubitemid 46742594)
6. Bellack, A. S., Morrison, R. L., Wixted, J. T., and, Mueser, K. T. 1990. An analysis of social competence in schizophrenia. The British Journal of Psychiatry, 156: 809-818. (Pubitemid 20207091)
7. Bellack, A. S., Bennett, M. E., Gearon, J. S., Brown, C. H., and, Yang, Y. 2006. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry, 63 (4): 426-432.
8. Beresford, T. P., Clapp, L., Martin, B., Wiberg, J. L., Alfers, J., and, Beresford, H. F. 2005. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. Journal of Clinical Psychopharmacology, 25 (4): 363-366. (Pubitemid 41060257)
9. Bowers, M. B., and, Swigar, M. E. 1983. Vulnerability to psychosis associated with hallucinogen use. Psychiatry Research, 9: 91-97. (Pubitemid 13026458)
10. Brady, K. T., Anton, R., Ballenger, J. C., Lydiard, R. B., Adinoff, B., and, Selander, J. 1990. Cocaine abuse among schizophrenic patients. American Journal of Psychiatry, 147: 1164-1167. (Pubitemid 20275368)
11. Brown, E. S., Nejtek, V. A., Perantie, D. C., Rajan Thomas, N., and, Rush, A. J. 2003. Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation. Journal of Clinical Psychopharmacology, 23 (4): 384-388. (Pubitemid 36951181)
12. Brown, E. S., Jeffress, J., Liggin, J. D., Garza, M., and, Beard, L. 2005. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Journal of Clinical Psychiatry, 66 (6): 756-760. (Pubitemid 40942423)
13. Brunette, M. F., Mueser, K. T., and, Drake, R. E. 2004. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug and Alcohol Review, 23 (4): 471-481. (Pubitemid 40019755)
14. Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., and, Keller, W. 2010. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36 (1): 71-93.
15. Bush, C. T., Langford, M. W., Rosen, P., and, Gott, W. 1990. Operation outreach: Intensive case management for severely psychiatrically disabled adults. Hospital & Community Psychiatry, 41 (6): 647-649. (Pubitemid 20230856)
16. Byerly, M. J., Nakonezny, P. A., and, Lescouflair, E. 2007. Antipsychotic medication adherence in schizophrenia. Psychiatric Clinics of North America, 30: 437-452. (Pubitemid 47284561)
17. Cantor-Graee, E., Nordstrom, L. G., and, McNeil, T. F. 2001. Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophrenia Research, 48: 69-82. (Pubitemid 32241184)
18. Chambers, R. A., Krystal, J. H., and, Self, D. W. 2001. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50: 71-83. (Pubitemid 32728207)
19. Chouljian, T. L., Shumway, M., and, Balanzio, E. 1995. Substance use among schizophrenia outpatients: Prevalence, course and relation to financial status. Annals of Clinical Psychiatry, 7: 19-24.
20. Cleghorn, J. M., Kaplan, R. D., Szechtman, B., Szechtman, H., Brown, G. M., and, Franco, S. 1991. Substance abuse and schizophrenia: Effect on symptoms but not neurocognitive function. Journal of Clinical Psychiatry, 52: 26-30.
21. Conley, R. R., Kelly, D. L., and, Gale, E. A. 1998. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophrenia Research, 33 (1-2): 95-101. (Pubitemid 28439250)
22. del Giudice, J., Clark, W. G., and, Gocka, E. F. 1975. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics, 16 (1): 32-36.
23. Dickey, B., and, Azeni, H. 1996. Persons with dual diagnoses of substance abuse and major mental illness: Their excess costs of psychiatric care. American Journal of Public Health, 86: 973-977. (Pubitemid 26242945)
24. Dickey, B., Normand, S. L., Weiss, R. D., Drake, R. E., and, Azeni, H. 2002. Medical morbidity, mental illness, and substance use disorders. Psychiatric Services, 53 (7): 861-867. (Pubitemid 34742769)
25. Dixon, L., Haas, G., Weiden, P. J., Sweeney, J., and, Frances, A. J. 1991. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. American Journal of Psychiatry, 148: 224-230.
26. Dixon, L. 1999. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophrenia Research, 35: 93-100.
27. Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., and, Kreyenbuhl, J. 2010. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bulletin, 36 (1): 48-70.
28. Drake, R. E., Osher, F. C., and, Wallach, M. A. 1989. Alcohol use and abuse in schizophrenia: A prospective community study. Journal of Nervous and Mental Disease, 177: 408-414. (Pubitemid 19185431)
29. Drake, R. E., Osher, F. C., Noordsy, D. L., Hurlbut, S. C., Teague, G. B., and, Beaudett, M. S. 1990. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin, 16: 57-67. (Pubitemid 20110375)
30. Drake, R. E., and, Wallach, M. A. 1993. Moderate drinking among people with severe mental illness. Hospital and Community Psychiatry, 44: 780-782. (Pubitemid 23226588)
31. Drake, R. E., Rosenberg, S. D., and, Mueser, K. T. 1996. Assessing substance use disorder in persons with severe mental illness. New Directions for Mental Health Services,: 3-17.
32. Drake, R. E., ONeal, E. L., and, Wallach, M. A. 2008. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment, 34 (1): 123-138. (Pubitemid 350216356)
33. Drebing, C. E., Van Ormer, E. A., Krebs, C., Rosenheck, R., Rounsaville, B., Herz, L., and, Penk, W. 2005. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. Journal of Applied Behavior Analysis, 38 (3): 359-372. (Pubitemid 43592186)
34. Fenton, W. S., Blyler, C. R., and, Heinssen, R. K. 1997. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23: 637-651. (Pubitemid 27485972)
35. Fleischhacker, W. W. 2009. Second-generation antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry Supplement, 52: S29-S36.
36. Fowler, I. L., Carr, V. J., Carter, N. T., and, Lewin, T. J. 1998. Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin, 24: 443-455. (Pubitemid 28378229)
37. Frisher, M., Collins, J., Millson, D., Crome, I., and, Croft, P. J. 2004. Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales. Journal of Epidemiology & Community Health, 58 (12): 1036-1041. (Pubitemid 39564206)
38. Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., and, Jeste, D. V. 2004. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry, 161 (4): 692-699. (Pubitemid 38445514)
39. Gitlin, M. J., Midha, K. K., Fogelson, D., and, Nuechterlein, K. 1988. Persistence of fluphenazine in plasma after decanoate withdrawal. Journal of Clinical Psychopharmacology, 8 (1): 53-56. (Pubitemid 18053898)
40. Goodman, L. A., Salyers, M. P., Mueser, K. T., Rosenberg, S. D., Swartz, M., Essock, S. M., and, Swanson, J. 2001. Recent victimization in women and men with severe mental illness: Prevalence and correlates. Journal of Traumatic Stress, 14: 615-632. (Pubitemid 34019917)
41. Green, A. I., Zimmet, S. V., Strouss, R. D., and, Schildkraut, J. J. 1999. Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harvard Review of Psychiatry, 6: 287-296. (Pubitemid 29132022)
42. Green, A. I., Tohen, M. F., Hamer, R. M., Strakowski, S. M., Lieberman, J. A., Glick, I., and HGDH Research Group. 2004. First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophrenia Research, 66: 125-135. (Pubitemid 38041110)
43. Green, A. I. 2005. Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. Journal of Clinical Psychiatry, 66 (Supplement 6): 21-26. (Pubitemid 41243258)
44. Haddad, P. M., Taylor, M., and, Niaz, O. S. 2009. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry, 195: S20-S28.
45. Haddock, G., Barrowclough, C., Tarrier, N., Moring, J., OBrien, R., Schofield, N., and, Lewis, S. 2003. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry, 183: 418-426. (Pubitemid 37357574)
46. Hambrecht, M., and, Hafner, H. 1996. Substance abuse and the onset of schizophrenia. Biological Psychiatry, 40: 1155-1163. (Pubitemid 26400880)
47. Hiday, V. A., Swartz, M. S., Swanson, J. W., Borum, R., and, Wagner, H. R. 1999. Criminal victimization of persons with severe mental illness. Psychiatric Services, 50: 62-68. (Pubitemid 29035358)
48. Hoff, R. A., and, Rosenheck, R. A. 1999. The cost of treating substance abuse patients with and without comorbid psychiatric disorders. Psychiatric Services, 50: 1309-1315. (Pubitemid 29468534)
49. Hogarty, G. E., Schooler, N. R., Ulrich, R., Mussare, F., Ferro, P., and, Herron, E. 1979. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry, 36 (12): 1283-1294. (Pubitemid 11145664)
50. Hough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., and, Eerdekens, M. 2010. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophrenia Research, 116: 107-117.
51. Hunt, G. E., Bergen, J., and, Bashir, M. 2002. Medication compliance and comorbid substance abuse in schizophrenia: Impact on community survival 4 years after a relapse. Schizophrenia Research, 54: 253-264. (Pubitemid 34304218)
52. Kane, J. M., Eerdekens, M., Lindenmayer, J. P., Keith, S. J., Lesem, M., and, Karcher, K. 2003. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry, 160 (6): 1125-1132. (Pubitemid 41070972)
53. Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D. Y., Bergstrom, R. F., and, McDonnell, D. 2010. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. American Journal of Psychiatry, 167 (2): 181-189.
54. Kavanagh, D. J., McGrath, J. J., and, Jenner, L. 2000. Substance use in psychotic disorders: Results from the Australian survey of mental health and wellbeing [abstract]. Acta Psychiatrica Scandinavica, 102 (Suppl. 404): 5
55. Kavanagh, D. J., McGrath, J., Saunders, J. B., Dore, G., and, Clark, D. 2002. Substance misuse in patients with schizophrenia: Epidemiology and management. Drugs, 62 (5): 743-755. (Pubitemid 34494020)
56. Kelly, D. L., Gale, E. A., and, Conley, R. R. 2003. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry, 48 (2): 111-114. (Pubitemid 36402212)
57. Kelly, T. M., Daley, D. C., and, Douaihy, A. B. 2012. Treatment of substance abusing patients with comorbid psychiatric disorders. Addictive Behaviors, 37 (1): 11-24.
58. Kramer, M., Litman, R., Hough, D., Lane, R., Lim, P., Liu, Y., and, Eerdekens, M. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. The International Journal of Neuropsychopharmacology, 13 (5): 635-647.
59. Kreyenbuhl, J., Slade, E. P., Medoff, D. R., Brown, C. H., Ehrenreich, B., Afful, J., and, Dixon, L. B. 2011. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Research, 131 (1-3): 127-132.
60. Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckban, S. G., and, Jeste, D. V. 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63: 892-909. (Pubitemid 35231730)
61. Lambert, M., Conus, P., Lubman, D. I., Wade, D., Yuen, H., Moritz, S., and, Schimmelmann, B. G. 2005. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 112: 141-148. (Pubitemid 41003193)
62. Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C. C., and, McDonnell, D. 2008. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. The Journal of Clinical Psychiatry, 69 (5): 790-799. (Pubitemid 351838688)
63. Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., and, Leucht, S. 2011. Oral versus depot antipsychotic drugs for schizophreniaA critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research, 127 (1-3): 83-92.
64. Levin, F. R., Evans, S. M., Kumaraswamy, S., Collins, E. D., Regent, N., and, Kleber, H. D. 1998. Fluphenazine treatment for cocaine abusers with schizophrenia: A pilot study. American Journal of Drug and Alcohol Abuse, 24: 343-360. (Pubitemid 28402492)
65. Liberman, R. P., Lillie, F., Falloon, I. R., Harpin, R. E., Hutchinson, W., and, Stoute, B. 1984. Social skills training with relapsing schizophrenics. An experimental analysis. Behavior Modification, 8 (2): 155-179. (Pubitemid 14080206)
66. Lindenmayer, J. 2010. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Journal of Neuropsychiatric Disease and Treatment, 6: 261-267.
67. Littrell, K. H., Petty, R. G., Hilligoss, N. M., Peabody, C. D., and, Johnson, C. G. 2001. Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse Treatment, 21 (4): 217-221. (Pubitemid 34041006)
68. Longo, L. P. 2002. Olanzapine for cocaine craving and relapse prevention in 2 patients. Journal of Clinical Psychiatry, 63 (7): 595-596. (Pubitemid 34787326)
69. Margolese, H. C., Malchy, L., Negrete, J. C., Tempier, R., and, Gill, K. 2004. Drug and alcohol use among patients with schizophrenia and related psychoses: Levels and consequences. Schizophrenia Research, 67: 157-166. (Pubitemid 38251445)
70. McEvoy, J. P., Freudenreich, O., Levin, E. D., and, Rose, J. E. 1995. Haloperidol increases smoking in patients with schizophrenia. Journal of Psychopharmacology, 119: 124-126.
71. McFarlane, W. R., Dixon, L., Lukens, E., and, Lucksted, A. 2003. Family psychoeducation and schizophrenia: A review of the literature. Journal of Marital and Family Therapy, 29 (2): 223-245. (Pubitemid 37513366)
72. Miles, H., and, Johnson, S. 2003. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatric Services, 54: 554-561. (Pubitemid 36752988)
73. Morrison, R. L., Bellack, A. S., and, Mueser, K. T. 1988. Deficits in facial-affect recognition and schizophrenia. Schizophrenia Bulletin, 14: 67-83.
74. Mueser, K. T., Yarnold, P. R., Levinson, D. F., Singh, H., Bellack, A. S., Lee, K., and, Yadalam, K. G. 1990. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophrenia Bulletin, 16: 31-56. (Pubitemid 20110374)
75. Mueser, K. T., Yarnold, P. R., Rosenberg, S. D., Swett, C. Jr., Miles, K. M., and, Hill, D. 2000. Substance use disorder in hospitalized severely mentally ill psychiatric patients: Prevalence, correlates, and subgroups. Schizophrenia Bulletin, 26: 179-192. (Pubitemid 30317704)
76. Norman, R. M., and, Malla, A. K. 2002. Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis. The Journal of Nervous and Mental Disease, 190: 331-334. (Pubitemid 34533665)
77. Nuechterlein, K. H., and, Dawson, M. E. 1984. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophrenia Bulletin, 10: 160-203.
78. Nyberg, S., Farde, L., and, Halldin, C. 1997. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Archives of General Psychiatry, 54 (10): 953-958.
79. Olfson, M., Mechanic, D., Hansell, S., Boyer, C. A., Walkup, J., and, Weiden, P. J. 2000. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services, 51: 216-222. (Pubitemid 30082525)
80. Olivera, A. A., Kiefer, M. W., and, Manley, N. K. 1990. Tardive dyskinesia in psychiatric patients with substance abuse. American Journal of Drug and Alcohol Abuse, 16: 57-66. (Pubitemid 20107092)
81. Owen, R. R., Fischer, E. P., Booth, B. M., and, Cuffel, B. J. 1996. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services, 47: 853-858. (Pubitemid 26264738)
82. Perkins, D. O. 2002. Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63: 1121-1128. (Pubitemid 36084056)
83. Perkins, D. O., Gu, H., Weiden, P. J., McEvoy, J. P., Hamer, R. M., and, Lieberman, J. A. 2008. Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry, 69 (1): 106-113. (Pubitemid 351282003)
84. Potvin, S., Stip, E., and, Roy, J. Y. 2003. Clozapine, quetiapine, and olanzapine among addicted schizophrenic patients: Towards testable hypothesis. International Clinical Psychopharmacology, 18 (3): 121-132. (Pubitemid 36575481)
85. Potvin, S., Stip, E., Lipp, O., Elie, R., Mancini-Mari, A., Demers, M. F., and, Gendron, A. 2006. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial. Current Medical Research & Opinion, 22 (7): 1277-1285. (Pubitemid 44085579)
86. Pristach, C. A., and, Smith, C. M. 1990. Medication compliance and substance abuse among schizophrenia patients. Hospital and Community Psychiatry, 41: 1345-1348.
87. Ries, R. K., Dyck, D. G., Short, R., Srebnik, D., Fisher, A., and, Comtois, K. A. 2004. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatric Services, 55 (4): 445-447. (Pubitemid 38445595)
88. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., and, Goodwin, F. K. 1990. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) study. The Journal of American Medical Association, 264: 2511-2518.
89. Rifkin, A., Quitkin, F., Rabiner, C. J., and, Klein, D. F. 1977. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Archives of General Psychiatry, 34 (1): 43-47. (Pubitemid 8023182)
90. Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L., Valley, D., and CSP555 Research Group. 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. The New England Journal of Medicine, 364 (9): 842-851.
91. Rubio, G., Martinez, I., Ponce, G., Jimenez-Arriero, M. A., Lopez-Munoz, F., and, Alamo, C. 2006. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry, 51: 531-539. (Pubitemid 44166341)
92. Schneier, F. R., and, Siris, S. G. 1987. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. The Journal of Nervous and Mental Disease, 175: 641-652. (Pubitemid 17163491)
93. Schooler, N. R., Levine, J., Severe, J. B., Brauzer, B., DiMascio, A., Klerman, G. L., and, Tuason, V. B. 1980. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Archives of General Psychiatry, 37 (1): 16-24. (Pubitemid 10139118)
94. Schooler, N. R. 2003. Relapse and rehospitalization: Comparing oral and depot antipsychotics. Journal of Clinical Psychiatry, 64 (Suppl. 16): 14-17. (Pubitemid 37523323)
95. Sevy, S., Robinson, D. G., Sunday, S., Napolitano, B., Miller, R., McCormack, J., and, Kane, J. 2011. Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. Psychiatry Research, 188 (3): 310-314.
96. Simpson, G. M., Mahmoud, R. A., Lasser, R. A., Kujawa, M., Bossie, C. A., Turkoz, I., and, Gharabawi, G. M. 2006. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. The Journal of Clinical Psychiatry, 67 (8): 1194-1203. (Pubitemid 44439690)
97. Siris, S. G. 1990. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophrenia Bulletin, 16: 111-122. (Pubitemid 20110380)
98. Siris, S. G., Kane, J. M., Frechen, K., Sellew, A. P., Mandeli, J., and, Fasano-Dube, B. 1988. Histories of substance abuse in patients with postpsychotic depressions. Comprehensive Psychiatry, 29 (6): 550-557. (Pubitemid 19010788)
99. Smelson, D. A., Losonczy, M. F., Davis, C. W., Kaune, M., Williams, J., and, Ziedonis, D. 2002. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry, 47: 671-675. (Pubitemid 35192034)
100. Soyka, M., Albus, M., Kathmann, N., Finelli, A., Hofstetter, S., Holzbach, R., and, Sand, P. 1993. Prevalence of alcohol and drug abuse in schizophrenic inpatients. European Archives of Psychiatry and Clinical Neuroscience, 242: 272-362.
101. Soyka, M., and, Sand, P. 1995. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry, 28 (2): 64-65.
102. Soyka, M. 2000a. Alcoholism and schizophrenia. Addiction, 95: 1613-1618.
103. Soyka, M. 2000b. Substance abuse, psychiatric disorder, and disturbed behavior. British Journal of Psychiatry, 176: 345-350.
104. Soyka, M., Aichmuller, C., von Bardeleben, U., Beneke, M., Glaser, T., Hornung-Knobel, S., and, Wegner, U. 2003. Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: Results from an open clinical study. European Addiction Research, 9: 65-72. (Pubitemid 36351186)
105. Stein, L. I., and, Test, M. A. 1980. Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation. Archives of General Psychiatry, 37 (4): 392-397. (Pubitemid 10100566)
106. Swadi, H., and, Bobier, C. 2003. Substance use disorders comorbidity among inpatient youths with psychiatric disorder. Australian and New Zealand Journal of Psychiatry, 37: 294-298. (Pubitemid 36833759)
107. Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Canive, J. M., and, Lieberman, J. A. 2006. Baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease, 194: 164-172.
108. Swofford, C. D., Kasckow, J. W., Scheeler-Gilkey, G., and, Inderbitzin, L. B. 1996. Substance use: A powerful predictor of relapse in schizophrenia. Schizophrenia Research, 20: 145-151. (Pubitemid 26387512)
109. Swofford, C. D., Scheller-Gilkey, G., Miller, A. H., Woolwine, B., and, Mance, R. 2000. Double jeopardy: Schizophrenia and substance abuse. American Journal of Drug and Alcohol Abuse, 26 (3): 343-353. (Pubitemid 30667001)
110. Tegeler, J., and, Lehmann, E. 1981. A follow-up study of schizophrenic outpatients treated with depot-neuroleptics. Progress in Neuropsychopharmacology, 5 (1): 79-90. (Pubitemid 11066665)
111. Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., and, Korhonen, P. 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. The American Journal of Psychiatry, 168 (6): 603-609.
112. Tsuang, J., Marder, S. R., Han, A., and, Hsieh, W. 2002. Olanzapine treatment for patients with schizophrenia and cocaine abuse. Journal of Clinical Psychiatry, 63 (12): 1180-1181. (Pubitemid 36084066)
113. Tsuang, J., and, Fong, T. W. 2004. Treatment of patients with schizophrenia and substance abuse disorders. Current Pharmaceutical Design, 10 (18): 2249-2261. (Pubitemid 38832767)
114. Valenstein, M., Ganoczy, D., McCarthy, J. F., Myra Kim, H., Lee, T. A., and, Blow, F. C. 2006. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: A retrospective review. Journal of Clinical Psychiatry, 67: 1542-1550. (Pubitemid 44787436)
115. Van Mastrigt, S., Addington, J., and, Addington, D. 2004. Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology, 39: 69-72. (Pubitemid 39369110)
116. Velligan, D. I., Wang, M., Diamond, P., Glahn, D. C., Castillo, D., Bendle, S., and, Miller, A. L. 2007. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services, 58 (9): 1187-1192. (Pubitemid 47507958)
117. Wade, D., Harrigan, S., Edwards, J., Burgess, P. M., Whelan, G., and, McGorry, P. D. 2006. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry, 189: 229-234. (Pubitemid 44343467)
118. Weiden, P., Rapkin, B., Zygmunt, A., Mott, T., Goldman, D., and, Frances, A. 1995. Post discharge medication compliance of inpatients converted from an oral depot neuroleptic regimen. Psychiatric Services, 46: 1049-1054.
119. Weiss, R. D., Griffin, M. L., Kolodziej, M. E., Greenfield, S. F., Najavits, L. M., Daley, D. C., and, Hennen, J. A. 2007. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. American Journal of Psychiatry, 164 (1): 100-107. (Pubitemid 46154787)
120. Wilk, J., Marcus, S. C., West, J., Countis, L., Hall, R., Regier, D. A., and, Olfson, M. 2006. Substance abuse and the management of medication nonadherence in schizophrenia. The Journal of Nervous and Mental Disease, 194: 454-457.
121. Wistedt, B., Wiles, D., and, Kolakowska, T. 1981. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet, 1 (8230): 1163 (Pubitemid 11105817)
122. Wobrock, T., Pajonk, F. G., DAmelio, R., and, Falkai, P. 2005. Schizophrenia and addiction. Psychoneuroendocrinology, 31 (9): 433-440.
123. Wobrock, T., and, Soyka, M. 2008. Pharmacotherapy of schizophrenia with comorbid substance use disorderreviewing the evidence and clinical recommendations. Progress in Neuro-psychopharmacology & Biological Psychiatry, 32 (6): 1375-1385.
124. Ziedonis, D. M. 2004. Integrated treatment of co-occurring mental illness and addiction: Clinical intervention, program, and system perspectives. CNS Spectrums, 9 (12): 892-904. 925
125. Zimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., and, Green, A. I. 2000. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. Journal of Clinical Psychopharmacology, 20 (1): 94-98. (Pubitemid 30056360)